Omaveloxolone

奥马索龙

Report date: 2025/05/21 14:52:02
NMEFirst In Class

Base Information

Drug NameOmaveloxolone
Drug Alias NameomaveloxolonaomaveloxolonumSKYCLARYSABT-RTA-408AT-RTA-408 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor erythroid 2-related factor 2 stimulants
TargetsNuclear factor erythroid 2-related factor 2
Therapy Area/IndicationsOcular inflammationPostoperative ComplicationsCataract +[11] 
Global Approved IndicationsFriedreich Ataxia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/02/28
Country/TerritoryCanadaUnited StatesNetherlands +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDartmouth CollegeThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBiogen US CorpReata Ireland LtdBiogen Inc +[4] 
Inactive CompaniesReata Pharmaceuticals Inc
Active IndicationsFriedreich Ataxia
Inactive IndicationsOcular inflammationPostoperative ComplicationsCataract +[10] 

Other Information

ATC CodeN/A
Related LinksN/A